Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

Earnings report AI-generated analysis

πŸ“‰ ISRG shares fell after earnings despite a 22% revenue increase.

πŸ€– Sales of da Vinci systems are not the main revenue driver; parts, accessories, and services account for roughly 75% of top-line revenue.

βš”οΈ Competition is heating up with Medtronic and Johnson & Johnson entering the surgical robotics market.

πŸ“ˆ ISRG sold more da Vinci systems in Q3 2026 than in Q3 2025, defying fears of growth stagnation.

πŸ₯ Procedures using da Vinci systems rose by 15% year over year, outpacing the 12% increase in installed systems.

πŸ’° ISRG's large installed base of over 12,000 systems creates a strong annuity-like cash flow machine.

🌍 The surgical robotics market is not yet saturated and offers ample room for global growth.

πŸ“Š Recurring income from parts and services provides a stable foundation despite new competition.

Bullish Signals
  • ISRG reported a 22% revenue jump in the quarter, demonstrating strong top-line performance.
  • The company sold more da Vinci systems in Q3 2026 than in the same quarter of 2025, proving continued unit growth.
  • Procedures using da Vinci systems increased by 15% year over year, significantly outpacing the 12% growth in installed systems.
  • ISRG possesses a massive installed base of over 12,000 systems that generates annuity-like cash flows from parts and services.
  • The majority of revenue comes from recurring sales of instruments, accessories, and services rather than one-time hardware sales.
Risk Factors
  • Intense competition is emerging as Medtronic and Johnson & Johnson enter the surgical robotics market with competing devices.
  • The stock price dropped following earnings, reflecting ongoing investor concerns about the competitive landscape despite strong fundamentals.
Full Analysis
Shares of Intuitive Surgical (NASDAQ: ISRG) declined following its earnings report on October 20, despite the company reporting a significant 22% revenue jump. The article argues that investors are overlooking the fact that sales of the da Vinci surgical robot systems are not the primary driver of the company's top line. Instead, recurring revenue from instruments, accessories, and services constitutes the majority of ISRG's business model. The report highlights that while competition from major medical device makers like Medtronic and Johnson & Johnson is intensifying, Intuitive Surgical continues to grow its installed base. In the third quarter of 2026, the company sold more da Vinci systems than in the same period of 2025. Furthermore, the number of procedures performed using da Vinci systems increased by 15% year over year, outpacing the 12% growth in installed systems, indicating strong underlying demand. Intuitive Surgical maintains a robust financial foundation with an installed base exceeding 12,000 systems, which generates annuity-like cash flows from parts and services. The article suggests that despite new entrants in the market, there is ample room for global growth as robotic surgery adoption expands. Although ISRG was not included in The Motley Fool's recent top 10 stock list, the analysis emphasizes its strong recurring income stream and non-saturation of the surgical robotics market.